Please login to the form below

Not currently logged in
Email:
Password:

idelalisib

This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

Novartis claims a rare win at ESMO for PI3K inhibitor class

Novartis claims a rare win at ESMO for PI3K inhibitor class

Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’  Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently

Latest news

  • Novartis considers filings for PI3K drug in breast cancer Novartis considers filings for PI3K drug in breast cancer

    At the moment no PI3K inhibitor has been approved for use in breast cancer, although Gilead Sciences’ Zydelig (idelalisib) has been used for certain types of leukaemia and lymphoma for several

  • Bayer bags speedy US approval for lymphoma drug Aliqopa Bayer bags speedy US approval for lymphoma drug Aliqopa

    Zydelig (idelalisib) – the first-in-class PI3k inhibitor – is approved for relapsed follicular lymphoma and also chronic lymphocytic leukaemia, but saw its commercial prospects scuppered last year after reports of serious

  • Bayer's lymphoma drug copanlisib gets speedy FDA review Bayer's lymphoma drug copanlisib gets speedy FDA review

    Bayer is in pursuit of Gilead Sciences' P13K inhibitor Zydelig (idelalisib), which is already approved for FL and chronic lymphocytic leukaemia (CLL) in the US but hasn't lived up to ... It's worth noting that idelalisib targets a single P13K isoform

  • EU clears AbbVie's leukaemia drug venetoclax EU clears AbbVie's leukaemia drug venetoclax

    have either failed chemoimmunotherapy or are unsuitable for treatment with a B-cell receptor pathway inhibitor such as AbbVie and Johnson &Johnson's Imbruvica (ibrutinib) or Gilead Science's Zydelig (idelalisib). ... had been previously treated with and

  • Roche in Roche in "unprecedented" launch period for new medicines

    Gazyva's gains came despite increased competition in the CLL market from drugs such as AbbVie/Johnson &Johnson's Imbruvica (ibrutinib) and Gilead Science's Zydelig (idelalisib) and a failed trial

More from news
Approximately 4 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics